Early COVID-19 Therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in Outpatient Settings Significantly Improved COVID-19 outcomes compared to Known outcomes in untreated patients, by Flavio A.Cadegiani, AndyGoren, Carlos G.Wambier, JohnMcCoy

Real science. Argue with the authors on their terms, which is how real science works, or shut up. From Flavio A.Cadegiani, AndyGoren, Carlos G.Wambier, and JohnMcCoy at “New Microbes and New Infections” via sciencedirect.com:

Highlights

Subjects with early COVID-19 treated with azithromycin combined with nitazoxanide, ivermectin or hydroxychloroquine showed overwhelming improvements compared to sex-, age-, disease-, and comorbidities-matched untreated patients.

Improvements with early treatments include reduction of up to 36.5% in viral shedding (p < 0.0001), 85% in disease duration (p < 0.0001), 95% in post-COVID symptoms, and 100% in respiratory complications, hospitalization, mechanical ventilations, deaths (p < 0.0001 for all). For every 1,000 confirmed cases for COVID-19, at least 140 hospitalizations, 50 mechanical ventilations and five deaths were prevented with treatment.

Because of the unquestionable benefits of the combination between early COVID-19 detection and early pharmacological approaches and the well-established safety profile of the drugs employed in the treatment regimens for COVID-19, it has become ethically questionable to conduct further studies employing full placebo arms in early COVID-19.

Abstract

In a prospective observational study (pre-AndroCoV Trial), the use of nitazoxanide, ivermectin and hydroxychloroquine demonstrated unexpected improvements in COVID-19 outcomes, when compared to untreated patients. The apparent yet likely positive results raised ethical concerns on the employment of further full placebo84 controlled studies in early stage COVID-19. The present analysis aimed to elucidate whether full placebo-control randomized clinical trials (RCTs) on early-stage COVID-19 are still ethically acceptable, through a comparative analysis with two control87 groups. Active group (AG) consisted of patients enrolled in the Pre AndroCoV-Trial (n = 585). Control Group 1 (CG1) consisted of a retrospectively obtained group of untreated patients of the same population (n = 137), and Control Group 2 (CG2) resulted from a precise prediction of clinical outcomes based on a thorough and structured review of indexed articles and official statements. Patients were matched for sex, age, comorbidities and disease severity at baseline. Compared to CG1 and CG2 AG showed reduction of 31.5-36.5% in viral shedding (p < 0.0001), 70-85% in disease duration (p < 0.0001), and 100% in respiratory complications, hospitalization, mechanical ventilations, and deaths (p < 0.0001 for all). For every 1,000 confirmed cases for COVID-19, at least 70 hospitalizations, 50 mechanical ventilations and five deaths were prevented. Benefits from the combination of early COVID-19 detection and early pharmacological approaches were consistent and overwhelming when compared to untreated groups, which, together with and well-established safety profile of the drug combinations tested in the Pre-AndroCoV Trial, precluded our study to continue employing full placebo in early COVID-19.

Continue reading→

One response to “Early COVID-19 Therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in Outpatient Settings Significantly Improved COVID-19 outcomes compared to Known outcomes in untreated patients, by Flavio A.Cadegiani, AndyGoren, Carlos G.Wambier, JohnMcCoy

  1. NITAXOXANIDE is a very useful multispectrum antibacterial,antiviral,antiviral shedding,anti-T.B.,antiprotozoan/parasite med. Proven to be useful against:flu-like symptoms,influenza a and b.,Avianflu,mers,pneumonia.It’s made in FLA.Pubmed#25108173 pmcid#pmc7113776.Other studies support this study’s conclusion.Theyve Known how to safely,cheaply treat covd and flu.

    Like

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.